(CercleFinance.com) – Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors.
In the phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly prolonged median PFS to 22.8 months compared to 8.5 months with high-dose octreotide LAR in patients with gastrointestinal neuroendocrine tumors. Newly diagnosed grade 2 and 3 advanced enteropancreatic NETs (GEP-NETs).
‘This is the first positive phase III trial of first-line radioligand treatment, and the overall efficacy and safety results are among the most clinically relevant observed to date in this type of advanced cancer, responding to a significant unmet need for patients. with newly diagnosed advanced GEP-NETs,’ said Jeff Legos, global head of oncology development at Novartis.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
